Bli medlem
Bli medlem

Du är här


Recipharm AB: Recipharm publishes prospectus

Not for release, publication or distribution, directly or indirectly,
in or into the United States, Canada, Australia, Japan, Hong Kong,
New Zealand, South Africa or any other jurisdiction where such
distribution of this press release would be subject to legal

The prospectus relating to Recipharm rights issue in the amount of
approximately SEK 805 million has been approved and registered by the
Swedish Financial Supervisory Authority and is now available on the
Company's website The prospectus and the
application forms will be sent by mail to directly registered
shareholders of Recipharm.

The prospectus and the application forms can be obtained from
Recipharm, Handelsbanken and Swedbank. The prospectus and the
application forms will also be available on Recipharm's website, on DNB
Markets' website, on Handelsbanken's website
investerings-erbjudande (only in Swedish) and on Swedbank's website, (only in Swedish).

DNB Markets, Handelsbanken Capital Markets and Swedbank Corporate
Finance are acting as financial advisors and Setterwalls Advokatbyrå
as legal advisor to Recipharm in connection with the rights issue.

Recipharm AB (publ)
The Board of Directors

For further information please visit or contact:
Thomas Eldered, CEO, +46 8 602 52 10
Björn Westberg, CFO,, +46 8 602 46 20

This information is published in accordance with the Swedish
Securities Market Act, the Swedish Financial Instruments Trading Act
and/or the regulations of Nasdaq Stockholm. This information was
submitted for publication on 19 May 2016, at 23:30hrs CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry employing some 3,200
employees. Recipharm offers manufacturing services of pharmaceuticals
in various dosage forms, production of clinical trial material and
APIs, and pharmaceutical product development. Recipharm manufactures
several hundred different products to customers ranging from Big
Pharma to smaller research- and development companies. Recipharm's
turnover is approximately SEK 4.6 billion and the Company operates
development and manufacturing facilities in France, Germany, India,
Israel, Italy, Portugal, Spain, Sweden and the UK and is
headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is
listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit

Important information
The information in this press release does not constitute an offer to
acquire, subscribe for or otherwise trade in shares, subscription
rights or other securities in Recipharm. Any invitation to the
persons concerned to subscribe for shares in Recipharm will only be
made through the prospectus that Recipharm estimates to publish on or
around 19 May 2016.

This press release may not be released, published or distributed,
directly or indirectly, in or into the United States, Australia,
Canada, Hong Kong, Japan, New Zealand, South Africa or any other
jurisdiction where such action is wholly or partially subject to
legal restrictions or where such action would require additional
prospectuses, registrations or other actions in addition to what
follows from Swedish law. Nor may the information in this press
release be forwarded, reproduced or disclosed in a manner that
contravenes such restrictions or would entail such requirements.
Failure to comply with this instruction may result in a violation of
applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares have or
will be registered under the U.S. Securities Act of 1933, as amended,
("Securities Act"), or securities legislation in any state or other
jurisdiction in the United States and may not be offered or sold,
directly or indirectly, in or into the United States, except pursuant
to an available exemption from the registration requirements of the
Securities Act and in compliance with the securities laws of any
state or other jurisdiction of the United States.

This press release may contain forward-looking statements which
reflect Recipharm's current view on future events and financial and
operational development. The words "intend", "estimate", "expect",
"may", "plan", "anticipate" or similar expressions regarding
indications or prognoses of future developments or trends and which
are not statements based on historical facts constitute
forward-looking information. Although Recipharm believes that these
statements are based on reasonable assumptions and expectations,
Recipharm cannot give any assurances that such statements will
materialize. Forward-looking statements are in its nature involved
with both known and unknown risks and uncertainties, since it is
depending on future events and circumstances. Forward-looking
statements do not constitute any representations and warranties and
the outcome could differ materially from the information set out in
the forward-looking statements.

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.